Anti-psoriasis efficacy testing for topical & injectable drugs
Explore InflammaSkin® for anti-psoriatic therapy testing
InflammaSkin® is a T cell–driven human skin inflammation model with a Th17/Th1 phenotype, designed to support the evaluation of anti-psoriatic therapies in a human-relevant context. The model can be used with topical, intradermal, or systemic-like treatment approaches and supports readouts including cytokine profiling, histological assessment, and spatial immune-cell analysis. Pharmacological testing with betamethasone showed reduced secretion of multiple pro-inflammatory cytokines, supporting the model’s responsiveness to immunomodulatory treatment.
Download the fact sheet to learn more about the InflammaSkin® model, available study approaches, and example pharmacological response data.
Please fill in the form below to access the fact sheet.
After submitting this form, you will receive an email with the link to access our fact sheet.
Want more research like this in your inbox? Subscribe to our newsletter →
Comments are closed.